MediMabBio’s pipelines include first-in-class antibody immunotherapies, which target an immune checkpoint inhibitor (ICI) and antagonistic or agonistic activity on the signaling receptor in different sets of immune cells. This is expected to induce anti-tumor immunity by stimulating effector T cells and inhibiting regulatory T cell activity. In order to modulate tumor microenvironment with optimized specificity and functionality, the company focuses on generating Neokine-tethered immunotherapeutic antibody, which has been developed through computational modelling and well-established MMB screening system.